0001209191-20-033320.txt : 20200601
0001209191-20-033320.hdr.sgml : 20200601
20200601214254
ACCESSION NUMBER: 0001209191-20-033320
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200528
FILED AS OF DATE: 20200601
DATE AS OF CHANGE: 20200601
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DRACHMAN JONATHAN G
CENTRAL INDEX KEY: 0001588467
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38800
FILM NUMBER: 20935477
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Harpoon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001708493
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473458693
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 OYSTER POINT BOULEVARD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-7400
MAIL ADDRESS:
STREET 1: 131 OYSTER POINT BOULEVARD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-28
0
0001708493
Harpoon Therapeutics, Inc.
HARP
0001588467
DRACHMAN JONATHAN G
C/O HARPOON THERAPEUTICS, INC.
131 OYSTER POINT BOULEVARD, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Director Stock Option (Right to Buy)
20.59
2020-05-28
4
A
0
10167
0.00
A
2030-05-27
Common Stock
10167
10167
D
Director Stock Option (Right to Buy)
20.59
2020-05-28
4
A
0
2880
0.00
A
2030-05-27
Common Stock
2880
2880
D
The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date.
The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of May 28, 2020 (on June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021), subject to the continuous service of the Reporting Person on each vesting date.
/s/ Jonathan Drachman by Christopher Whitmore, Attorney-in-Fact
2020-06-01